Copy Link Print Information

Adezmapimod hydrochloride

(Synonyms: SB 203580 hydrochloride; RWJ 64809 hydrochloride)
626 Cited Publications
Customer Review

Based on 626 publication(s) in Google Scholar

Adezmapimod (SB 203580; RWJ 64809) hydrochloride is a selective and ATP-competitive p38 MAPK inhibitor with IC50s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod hydrochloride inhibits LCK, GSK3β and PKBα with IC50s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod hydrochloride does not disrupt JNK activity and is an autophagy and mitophagy activator.

For research use only. We do not sell to patients.

  • Purity: 99.37%
  • CAS No.: 869185-85-3
  • Formula: C21H17ClFN3OS
  • Molecular Weight:413.90
  • Storage:

    4°C, sealed storage, away from moisture

    * In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)

  • Adezmapimod hydrochloride Chemical Structure
    Adezmapimod hydrochloride Chemical Structure
  • Experimental Validation Results for Adezmapimod hydrochloride
  • Experimental Validation Results for Adezmapimod hydrochloride
  • Experimental Validation Results for Adezmapimod hydrochloride
  • Experimental Validation Results for Adezmapimod hydrochloride
  • Experimental Validation Results for Adezmapimod hydrochloride
  • Experimental Validation Results for Adezmapimod hydrochloride
  • Experimental Validation Results for Adezmapimod hydrochloride
  • Experimental Validation Results for Adezmapimod hydrochloride
  • Experimental Validation Results for Adezmapimod hydrochloride
  • Experimental Validation Results for Adezmapimod hydrochloride
  • Experimental Validation Results for Adezmapimod hydrochloride
  • Experimental Validation Results for Adezmapimod hydrochloride
  • Experimental Validation Results for Adezmapimod hydrochloride
  • Experimental Validation Results for Adezmapimod hydrochloride
  • Experimental Validation Results for Adezmapimod hydrochloride
  • Experimental Validation Results for Adezmapimod hydrochloride
  • Experimental Validation Results for Adezmapimod hydrochloride
  • Experimental Validation Results for Adezmapimod hydrochloride
  • Experimental Validation Results for Adezmapimod hydrochloride
  • Experimental Validation Results for Adezmapimod hydrochloride
  • Experimental Validation Results for Adezmapimod hydrochloride
  • Experimental Validation Results for Adezmapimod hydrochloride
  • Experimental Validation Results for Adezmapimod hydrochloride
  • Experimental Validation Results for Adezmapimod hydrochloride
  • Experimental Validation Results for Adezmapimod hydrochloride
  • Experimental Validation Results for Adezmapimod hydrochloride
  • Experimental Validation Results for Adezmapimod hydrochloride
  • Experimental Validation Results for Adezmapimod hydrochloride
  • Experimental Validation Results for Adezmapimod hydrochloride
  • Experimental Validation Results for Adezmapimod hydrochloride
  • Experimental Validation Results for Adezmapimod hydrochloride
  • Experimental Validation Results for Adezmapimod hydrochloride
  • Experimental Validation Results for Adezmapimod hydrochloride
  • Experimental Validation Results for Adezmapimod hydrochloride
  • Experimental Validation Results for Adezmapimod hydrochloride
  • Experimental Validation Results for Adezmapimod hydrochloride
  • Experimental Validation Results for Adezmapimod hydrochloride
CAS No.: 869185-85-3
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Adezmapimod hydrochloride:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Adezmapimod hydrochloride

More
Customer Validation & Images
IFWBIHCRT-PCR
  • RT-PCR
  • WB
  • RT-PCR
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • IF
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • IHC
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • IF
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB

All p38 MAPK Isoforms

More
Keywords
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Adezmapimod hydrochloride Chemical Structure
    Adezmapimod hydrochloride Chemical Structure
    1/16
  • 1/16

    Adezmapimod hydrochloride purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2021 Jan;41(1):62-78. [Abstract]

    Customer Validation
     Cells pre-treated with P38 inhibitor SB203580 (SB2, 10 μmol/L) for 6 h were further stimulated with EGF (20 ng/mL) for 24 h, then PD-L1 and HLA-B transcription was detected by qRT-PCR.

  • 1/16

    Adezmapimod hydrochloride purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2021 Jan;41(1):62-78. [Abstract]

    Customer Validation
     Cells pre-treated with P38 inhibitor SB203580 (SB2, 10 μmol/L) for 6 h were further stimulated with EGF (20 ng/mL) for 24 h, then PD-L1 and HLA-ABC protein levels were measured by Western blotting.

  • 1/16

    Adezmapimod hydrochloride purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2021 Jan;41(1):62-78. [Abstract]

    Customer Validation
     Cells were pre-treated with SB203580 (Adezmapimod) (10 μmol/L) or dimethylsulfoxide (DMSO) for 6 h, and then co-stimulated with or without EGF for an additional 24 h, next cells were further treated with actinomycin D (5 μg/mL) for 0-120 min, and cellular PD-L1 mRNA expression was detected by qRT-PCR.

  • 1/16

    Adezmapimod hydrochloride purchased from MedChemExpress. Usage Cited in: FASEB J. 2019 Feb;33(2):2435-2450. [Abstract]

    Customer Validation
     Bile acids (BAs) cause nuclear translocation of NF-kB p65, an effect that is abolished by SB203580.

  • 1/16

    Adezmapimod hydrochloride purchased from MedChemExpress. Usage Cited in: J Cell Biochem. 2019 May;120(5):8561-8569. [Abstract]

    Customer Validation
     Western analysis of protein expression in the treatment of miR-543 and SB 203580.

  • 1/16

    Adezmapimod hydrochloride purchased from MedChemExpress. Usage Cited in: Biomaterials. 2018 Aug:175:19-29. [Abstract]

    Customer Validation
     Western blotting analysis showing the related protein expression (MHC, MyoD, p38α, phospho-p38α) of C2C12 myoblasts after incubated for 6 days in DM containing 40 μg/mL AuNPs and Au-AgNPs in the presence or absence of SB203580 (SB).

  • 1/16

    Adezmapimod hydrochloride purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2018 Jun 15;15(1):184. [Abstract]

    Customer Validation
     Representative immunoblots of total lysates from BV2 cells treated with MPP+or/and U0126 (10 μM), SP600125 (SP, 10 μM) and SB203580 (SB, 10 μM) using the antibodies against DICER.

  • 1/16

    Adezmapimod hydrochloride purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2018 Mar 15:42:152-163. [Abstract]

    Customer Validation
     Cells are pretreated with SP600125 (20 μM), SB203580 (20 μM) or U0126 (20 μM) in presence or absence of KLA, then incubated with LPS (1 μg/mL) for certain time. Cell lysates are subjected to western blot.

  • 1/16

    Adezmapimod hydrochloride purchased from MedChemExpress. Usage Cited in: Br J Pharmacol. 2018 Dec;175(23):4338-4352. [Abstract]

    Customer Validation
     Treatment of macrophages with inhibitor of p38 (SB203580) or JNK (SP600125) inhibits the synthesis of pro-IL-1β in ZFP91-overexpressing THP-1 cells.

  • 1/16

    Adezmapimod hydrochloride purchased from MedChemExpress. Usage Cited in: Front Immunol. 2018 Dec 7:9:2854. [Abstract]

    Customer Validation
     Neutrophils are pretreated with inhibitor of p38 MAPK (SB203580 (Adezmapimod)) and ERK1/2 (U0126), and the cells are then incubated with either SS2 ZY05719 or PMA for 3 h. Immunofluorescence is performed.

  • 1/16

    Adezmapimod hydrochloride purchased from MedChemExpress. Usage Cited in: PLoS Biol. 2018 May 11;16(5):e2004225. [Abstract]

    Customer Validation
     Representative western blots of p-CREB (Ser133) and UCP-1 in iWAT from C57BL/6J mice after 4 wk of SB203580 treatment. These mice are exposed to cold for 2 d before analysis.

  • 1/16

    Adezmapimod hydrochloride purchased from MedChemExpress. Usage Cited in: J Agric Food Chem. 2018 Jun 27;66(25):6317-6325. [Abstract]

    Customer Validation
     HepG2 cells are pre-incubated with 20 µM SB203580, SP600125 and PD98059 for 1 h and then treated with tangeretin(20µM) for 24 h.

  • 1/16

    Adezmapimod hydrochloride purchased from MedChemExpress. Usage Cited in: Acta Physiol (Oxf). 2018 Feb;222(2). [Abstract]

    Customer Validation
     P38 inhibitor SB203580 (Adezmapimod) pretreatment also decreases p-HSP27 and MMP9 levels induced by MICAL2-overexpression.

  • 1/16

    Adezmapimod hydrochloride purchased from MedChemExpress. Usage Cited in: Am J Physiol Cell Physiol. 2018 Aug 1;315(2):C225-C235. [Abstract]

    Customer Validation
     Western blot analysis shows that inhibiting MAPK cannot completely reverse increased expression of RNF2 and CDDP resistance of OC cells.

  • 1/16

    Adezmapimod hydrochloride purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2018 Nov;22(11):5450-5467. [Abstract]

    Customer Validation
     Treatment with SB203580 (Adezmapimod) significantly abolishes siPlectin-stimulated p38 activation.

  • 1/16

    Adezmapimod hydrochloride purchased from MedChemExpress. Usage Cited in: J Endod. 2018 May;44(5):751-758. [Abstract]

    Customer Validation
     p38 MAPK inhibition enhances DPC-Exos–induced tube formation. (A) p38 MAPK activity is measured by detecting Phospho-p38 MAPK. The ratio between Phospho-p38 MAPK and the p38 MAPK band is used for quantification. (B) The effects of VEGF-A and KDR expression after p38 MAPK inhibitor SB203580 treatment on DPC-Exos-stimulated HUVECs.

  • 1/16

    Adezmapimod hydrochloride purchased from MedChemExpress. Usage Cited in: BMC Pulm Med. 2018 Nov 27;18(1):178. [Abstract]

    Customer Validation
     P-p38 and P-Hsp27 are detected by western blotting with the treatment of LPS, SB203580 and SB203580+ LPS.

  • 1/16

    Adezmapimod hydrochloride purchased from MedChemExpress. Usage Cited in: BMC Pulm Med. 2018 Nov 27;18(1):178. [Abstract]

    Customer Validation
     P-p38 and P-Hsp27 are detected by western blotting with the treatment of LPS, SB203580 and SB203580+ LPS.

  • 1/16

    Adezmapimod hydrochloride purchased from MedChemExpress. Usage Cited in: J Cell Biochem. 2018 Nov;119(10):8450-8459. [Abstract]

    Customer Validation
     Western blot results show a reduction in phosphorylated p38 MAPK in ADSCs after treatment with 20 μM SB203580, 20 μM SP600125, or 20 μM PD98059 for 1 hour.

  • 1/16

    Adezmapimod hydrochloride purchased from MedChemExpress. Usage Cited in: Cell Physiol Biochem. 2018;46(5):1779-1792. [Abstract]

    Customer Validation
     Western blot bands of p38, phospho-p38, ZO-1, Clau-din-1, and Occludin. JNK inhibitor SP600125 and p38 inhibitor SB203580 are used.

  • 1/16

    Adezmapimod hydrochloride purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2018 Dec:108:1294-1302. [Abstract]

    Customer Validation
     The protein levels of IL-1β and TNF-α are sharply downregulated by the addition of inhibitors SB203580, SP600125, and U0126.

  • 1/16

    Adezmapimod hydrochloride purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2018 Dec:108:1294-1302. [Abstract]

    Customer Validation
     The protein level of MMP-9 is downregulated by inhibitors SB203580, SP600125, and U0126.

  • 1/16

    Adezmapimod hydrochloride purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2018 Dec:108:1294-1302. [Abstract]

    Customer Validation
     As for both 0 g and 3 g groups, the p-ERK1/2/ERK1/2 is notably reduced by inhibitors SB203580, SP600125, and U0126.

  • 1/16

    Adezmapimod hydrochloride purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2018 Dec:108:1294-1302. [Abstract]

    Customer Validation
     As for both 0 g and 3 g groups, the p-p38&p38 is downregulated by inhibitors SB203580, SP600125, and U0126.

  • 1/16

    Adezmapimod hydrochloride purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2018 Dec:108:1294-1302. [Abstract]

    Customer Validation
     As for both 0 g and 3 g groups, the p-JNK1&JNK1 is downregulated by inhibitors SB203580, SP600125, and U0126.

  • 1/16

    Adezmapimod hydrochloride purchased from MedChemExpress. Usage Cited in: Cell Death Differ. 2017 Mar;24(3):492-499. [Abstract]

    Customer Validation
     LPS stimulates ICER expression via p38-CREB pathway. Effect of MAPK and IKK inhibitors on LPS-induced CREB phosphorylation in peritoneal macrophages.

  • 1/16

    Adezmapimod hydrochloride purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2017 May 1:393:22-32. [Abstract]

    Customer Validation
     Effects of p38 MAPK inhibitor (SB203580), ERK inhibitor (U0126), JNK inhibitor (SP600125), caspase inhibitor (Z-VAD-FMK) and NAC on SGC-7901 and MGC-803 treated with DOX/VCPA combination treatment. VCPA pretreatment strategy is the same as above. SB203580 (20 μM), U0126 (10 μM), SP600125 (20 μM), Z-VAD-FMK (10 μM) and NAC (5 mM) are treated 2 h before DOX (2 μg/mL) added into the culture, respectively. MAPK pathway protein levels are determined.

  • 1/16

    Adezmapimod hydrochloride purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2017 Nov:112:49-59. [Abstract]

    Customer Validation
     Cells are pre-treated with ERK (U1026) and p38 (SB203580) inhibitors, followed by GL-V9 treatment for 24 h. Western blot is performed to analyze NAG-1 expression.

  • 1/16

    Adezmapimod hydrochloride purchased from MedChemExpress. Usage Cited in: Hum Mol Genet. 2017 Sep 15;26(18):3553-3563. [Abstract]

    Customer Validation
     Immunofluorescence analysis for expression of the I-cell marker ΔNP63 on proximal sections of ureters explanted from E12.5 wildtype (control) embryos and cultured for 6 d in the presence of solvent (DMSO) (A), the AKT inhibitor (AKT-i) MK2206 (B), the P38 inhibitor (P38-i) SB203580 (C), the ERK1/2 inhibitor (ERK1/2-i) PD98059 (D) or combinations as indicated (E and F).

  • 1/16

    Adezmapimod hydrochloride purchased from MedChemExpress. Usage Cited in: Biochem Cell Biol. 2017 Feb;95(1):64-68. [Abstract]

    Customer Validation
     The involvement of the p38 MAPK signaling pathways in lactoferrin-induced differentiation of HaCaT keratinocytes. HaCaT cells are differentiated in the presence or absence of 10 μM bovine Lactoferrin for 5 days. PD98059 (40 μM), SB203580 (10 μM), or LY294002 (10 μM) are added at the same time. Cell differentiation is evaluated by the expression levels of Involucrin and Filaggrin. GAPDH is used as a loading control.

  • 1/16

    Adezmapimod hydrochloride purchased from MedChemExpress. Usage Cited in: Biomed Res. 2017; 28 (8): 3383-3386

    Customer Validation
     Effects of various protease inhibitors on HO-1 and P-gp protein expressions.

  • 1/16

    Adezmapimod hydrochloride purchased from MedChemExpress. Usage Cited in: Int J Clin Exp Med. 2017;10(9):13542-13549.

    Customer Validation
     SB203580 decreases the expression ratio of p-p38 and p38 to inhibit activation of p38 MARK pathway.

  • 1/16

    Adezmapimod hydrochloride purchased from MedChemExpress. Usage Cited in: Oxid Med Cell Longev. 2017:2017:6175841. [Abstract]

    Customer Validation
     Involvements of MAPK signaling pathway in CPS-induced apoptosis in ALI cultures of sheep bronchial epithelial cells. Cells are pretreated with SB203580 (a P38 inhibitor, 20 μM) for 1 h, followed by exposure to CPS (100 ng/mL) or MO (MOI = 30) for 48 h. Cell lysates are subjected to Western blotting analysis using indicated antibodies.

  • 1/16

    Adezmapimod hydrochloride purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Oct 19;8(60):101965-101983. [Abstract]

    Customer Validation
     Representative western blot analysis of P-gp, p38 MAPK and phospho-p38 MAPK expression in MCF-7/MDR and K562/MDR cells treated with 10 μM SB203580 for 48 hr.

  • 1/16

    Adezmapimod hydrochloride purchased from MedChemExpress. Usage Cited in: China Biotechnology. 2017, 37(12): 40-48.

    Customer Validation
     The Western blot analysis of HOG1 and Phospho-HOG1.

  • 1/16

    Adezmapimod hydrochloride purchased from MedChemExpress. Usage Cited in: Chin Arch Otolaryngol Head Neck Surg. 2016,23(01):49-52.

    Customer Validation
     Effect of p38MAPK inhibitor on the soft palate reconstruction of the rats with chronic intermittent hypoxia.

  • 1/16

    Adezmapimod hydrochloride purchased from MedChemExpress. Usage Cited in: J Mol Cell Cardiol. 2015 Dec;89(Pt B):268-79. [Abstract]

    Customer Validation
     Dose response of MAPK and Akt inhibitors on cardiac fibroblast-derived exosomes (Exo)-induced activation of MAPKs and Akt. Neonatal rat cardiomyocytes are treated with or without Exo (50 μg/mL), U0126, SP600125, MK-2206, and SB023580 for 20 min and subjected to Western blot analysis. The results are from 4 separate experiments.

  • Adezmapimod hydrochloride